By Dr Anthony Luke Byrne

Preprints

Almeida C; Durand R; LaHood A; Byrne A; Mendoza-Ticona A; Ygnacio E; Durand F; Lecca L; Pita R; Guerra D; Wong M; Tintaya K; Mitnick C, 2024, “I have to breathe”: A mixed-methods pilot study to assess the feasibility, acceptability, cost, and effectiveness of an intervention for post-tuberculosis lung disease, , http://dx.doi.org/10.21203/rs.3.rs-3813549/v1

Dupnik K; Rivera VR; Dorvil N; Akbarnejad H; Gao Y; Liu J; Apollon A; Dumond E; Riviere C; Severe P; Lavoile K; Duran Mendicuti MA; Pierre S; Rouzier V; Walsh KF; Byrne AL; Joseph P; Cremieux P-Y; Pape JW; Koenig SP, 2023, Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification among Patients with Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-Income Countries., , http://dx.doi.org/10.1101/2023.12.19.23300232

Phetsouphanh C; Jacka B; Ballouz S; Jackson KJL; Wilson D; Manandhar B; Klemm V; Tan H-X; Wheatley A; Aggarwal A; Akerman A; Milogiannakis V; Starr M; Cunningham P; Turville S; Kent S; Byrne A; Brew B; Darley D; Dore G; Kelleher A; Matthews G, 2023, Improvement of immune dysregulation and health-related quality of life in individuals with long COVID at 24-months following SARS-CoV-2 infection, , http://dx.doi.org/10.1101/2023.08.27.23294704

Cysique L; Jakabek D; Bracken S; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Pires AS; Darley D; Byrne A; Phetsouphanh C; Kelleher A; Dore G; Matthews G; Guillemin G; Brew B, 2022, Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study, , http://dx.doi.org/10.1101/2022.06.07.22276020

Menzies N; Quaife M; Allwood BW; Byrne AL; Coussens AK; Harries AD; Marx FM; Meghji J; Pedrazzoli D; Salomon JA; Sweeney S; van Kampen SC; Wallis RS; Houben RMGJ; Cohen T, The Lifetime Burden of Disease Due to Incident Tuberculosis: A Global Re-Appraisal Including Post-TB Sequelae, , http://dx.doi.org/10.2139/ssrn.3944911

Back to profile page